Comprehensive Set of Tertiary Complex Structures and Palmitic Acid Binding Provide Molecular Insights into Ligand Design for RXR Isoforms

被引:22
作者
Chaikuad, Apirat [1 ,2 ]
Pollinger, Julius [1 ]
Ruehl, Michael [1 ]
Ni, Xiaomin [1 ,2 ]
Kilu, Whitney [1 ]
Heering, Jan [3 ]
Merk, Daniel [1 ]
机构
[1] Goethe Univ Frankfurt, Inst Pharmaceut Chem, Max von Laue Str 9, D-60438 Frankfurt, Germany
[2] Goethe Univ Frankfurt, BMLS, Struct Genom Consortium, Max von Laue Str 15, D-60438 Frankfurt, Germany
[3] Fraunhofer Inst Mol Biol & Appl Ecol IME, Branch Translat Med & Pharmacol TMP, Theodor Stern Kai 7, D-60596 Frankfurt, Germany
关键词
nuclear receptor; retinoid X receptor; stearic acid; neurodegeneration; RETINOID-X-RECEPTOR; AGONIST; PHARMACOLOGY; MODULATORS; DEFICITS; CELLS; DRUG;
D O I
10.3390/ijms21228457
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The retinoid X receptor (RXR) is a ligand-sensing transcription factor acting mainly as a universal heterodimer partner for other nuclear receptors. Despite presenting as a potential therapeutic target for cancer and neurodegeneration, adverse effects typically observed for RXR agonists, likely due to the lack of isoform selectivity, limit chemotherapeutic application of currently available RXR ligands. The three human RXR isoforms exhibit different expression patterns; however, they share high sequence similarity, presenting a major obstacle toward the development of subtype-selective ligands. Here, we report the discovery of the saturated fatty acid, palmitic acid, as an RXR ligand and disclose a uniform set of crystal structures of all three RXR isoforms in an active conformation induced by palmitic acid. A structural comparison revealed subtle differences among the RXR subtypes. We also observed an ability of palmitic acid as well as myristic acid and stearic acid to induce recruitment of steroid receptor co-activator 1 to the RXR ligand-binding domain with low micromolar potencies. With the high, millimolar endogenous concentrations of these highly abundant lipids, our results suggest their potential involvement in RXR signaling.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 54 条
[1]   Comprehensive Profiling of Plasma Fatty Acid Concentrations in Young Healthy Canadian Adults [J].
Abdelmagid, Salma A. ;
Clarke, Shannon E. ;
Nielsen, Daiva E. ;
Badawi, Alaa ;
El-Sohemy, Ahmed ;
Mutch, David M. ;
Ma, David W. L. .
PLOS ONE, 2015, 10 (02)
[2]   THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Nuclear hormone receptors [J].
Alexander, Stephen P. H. ;
Cidlowski, John A. ;
Kelly, Eamonn ;
Marrion, Neil V. ;
Peters, John A. ;
Faccenda, Elena ;
Harding, Simon D. ;
Pawson, Adam J. ;
Sharman, Joanna L. ;
Southan, Christopher ;
Davies, Jamie A. .
BRITISH JOURNAL OF PHARMACOLOGY, 2017, 174 :S208-S224
[3]  
Auwerx J, 1999, CELL, V97, P161
[4]   Reversal of apoE4-Driven Brain Pathology and Behavioral Deficits by Bexarotene [J].
Boehm-Cagan, Anat ;
Michaelson, Daniel M. .
JOURNAL OF NEUROSCIENCE, 2014, 34 (21) :7293-7301
[5]   Defining the Communication between Agonist and Coactivator Binding in the Retinoid X Receptor α Ligand Binding Domain [J].
Boerma, LeeAnn J. ;
Xia, Gang ;
Qui, Cheng ;
Cox, Bryan D. ;
Chalmers, Michael J. ;
Smith, Craig D. ;
Lobo-Ruppert, Susan ;
Griffin, Patrick R. ;
Muccio, Donald D. ;
Renfrow, Matthew B. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (02) :814-826
[6]   Defined PEG smears as an alternative approach to enhance the search for crystallization conditions and crystal-quality improvement in reduced screens [J].
Chaikuad, Apirat ;
Knapp, Stefan ;
von Delft, Frank .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2015, 71 :1627-1639
[7]  
Chandraratna RAS, 2016, AM J TRANSL RES, V8, P1016
[8]   ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models [J].
Cramer, Paige E. ;
Cirrito, John R. ;
Wesson, Daniel W. ;
Lee, C. Y. Daniel ;
Karlo, J. Colleen ;
Zinn, Adriana E. ;
Casali, Brad T. ;
Restivo, Jessica L. ;
Goebel, Whitney D. ;
James, Michael J. ;
Brunden, Kurt R. ;
Wilson, Donald A. ;
Landreth, Gary E. .
SCIENCE, 2012, 335 (6075) :1503-1506
[9]   Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease [J].
Cummings, Jeffrey L. ;
Zhong, Kate ;
Kinney, Jefferson W. ;
Heaney, Chelcie ;
Moll-Tudla, Joanne ;
Joshi, Abhinay ;
Pontecorvo, Michael ;
Devous, Michael ;
Tang, Anne ;
Bena, James .
ALZHEIMERS RESEARCH & THERAPY, 2016, 8
[10]   Design of selective nuclear receptor modulators: RAR and RXR as a case study [J].
de Lera, Angel R. ;
Bourguet, William ;
Altucci, Lucia ;
Gronemeyer, Hinrich .
NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (10) :811-820